Document is current
Any future updates will be listed below
-
Authors
Kattelus, Roosa
Starskaia, Inna
Lindén, Markus
Batkulwar, Kedar
Pietilä, Sami
Moulder, Robert
Marson, Alexander
Rasool, Omid
Suomi, Tomi
Elo, Laura L.
Lahesmaa, Riitta
Buchacher, Tanja https://orcid.org/0000-0003-1937-2202
-
Funding
Funding for this research was provided by:
University of Turku
- License Information
-
More Information
Article History
Received: 26 June 2024
Revised: 20 August 2024
Accepted: 27 August 2024
First Online: 12 September 2024
Declarations
:
: The umbilical cord blood was collected from anonymous donors at Turku University Hospital and the use of it was approved by of the Ethics Committee of the Hospital District of Southwest Finland (24.11.1998 article 323).
: A.M. is a cofounder of Site Tx, Arsenal Biosciences, Spotlight Therapeutics and Survey Genomics, serves on the boards of directors at Site Tx, Spotlight Therapeutics and Survey Genomics, is a member of the scientific advisory boards of Site Tx, Arsenal Biosciences, Spotlight Therapeutics, Survey Genomics, NewLimit, Amgen, and Tenaya, owns stock in Arsenal Biosciences, Site Tx, Spotlight Therapeutics, NewLimit, Survey Genomics, Tenaya and Lightcast and has received fees from Site Tx, Arsenal Biosciences, Spotlight Therapeutics, NewLimit, 23andMe, PACT Pharma, Juno Therapeutics, Tenaya, Lightcast, Trizell, Vertex, Merck, Amgen, Genentech, GLG, ClearView Healthcare, AlphaSights, Rupert Case Management, Bernstein and ALDA. A.M. is an investor in and informal advisor to Offline Ventures and a client of EPIQ. The Marson laboratory has received research support from the Parker Institute for Cancer Immunotherapy, the Emerson Collective, Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead and Anthem and reagents from Genscript and Illumina.The other authors declare no competing interests.
